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Objective/background: The development of new tools capable of targeting Mycobacterium
tuberculosis (Mtb)-infected cells have potential applications in diagnosis, treatment, and
prevention of tuberculosis. In Mtb-infected cells, CD1b molecules present Mtb lipids to
the immune system (Mtb lipid–CD1b complexes). Because of the lack of CD1b polymor-
phism, specific Mtb lipid–CD1b complexes could be considered as universal Mtb infection
markers. 2-Stearoyl-3-hydroxyphthioceranoyl-20-sulfate-a-a0-D-trehalose (Ac2SGL) is speci-
fic for Mtb, and is not present in other mycobacterial species. The CD1b–Ac2SGL complexes
are expressed on the surface of human cells infected with Mtb. The aim of this study was to
generate ligands capable of binding these CD1b–Ac2SGL complexes.
Methods: A synthetic human scFv phage antibody library was used to select
phage-displayed antibody fragments that recognized CD1b–Ac2SGL using CD1b-
transfected THP-1 cells loaded with Ac2SGL., Malaysia;
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(dAbj11)—showed high relative binding to the Ac2SGL–CD1b complex.
Conclusion: A ligand recognizing the Ac2SGL–CD1b complex was obtained, which
is a potential candidate to be further tested for diagnostic and therapeutic
applications.
 2016 Production and hosting by Elsevier Ltd. on behalf of Asian African Society for
Mycobacteriology.Introduction
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb),
continues to be one of the leading causes of infectious dis-
ease morbidity and mortality, with reports estimating more
than 1.5 million TB-related deaths annually [1,2]. Prevention
of transmission remains one of the most effective control
strategies, and therefore, there is an urgent need for gener-
ation of new tools useful for early and rapid diagnosis.
Lipids, glycolipids, and lipopeptides derived from Mtb are
presented to T cells by nonpolymorphic CD1 cell-surface
molecules [3–5], thereby expanding the possible targets
available to the adaptive immune system for controlling
infections [5]. Patients recently infected with Mtb have
CD1-restricted T-cell responses to a lipid antigen [6]. Presen-
tation of lipid antigens to T cells has been described in TB,
in association with CD1b molecules [7,8]. Importantly, a
lipid antigen belonging to the group of diacylated sulfogly-
colipids purified from Mtb (2-stearoyl-3-hydroxyphthiocera
noyl-20-sulfate-a-a0-D-trehalose [Ac2SGL]) has been identified.
Specific T cells recognizing the CD1b–Ac2SGL are present in
TB patients and in purified protein derivative (PPD)-positive,
but not in PPD-negative, individuals [4]. The identification of
cells infected with specific microorganisms is an important
objective for the development of new diagnostic and thera-
peutic approaches. In this regard, the development of
ligands with specificity to complexes of human leukocyte
antigen molecules and peptide epitopes has been reported,
however, the main disadvantage of this approach lies on
the limited recognition spectrum associated with the high
polymorphism of the major histocompatibility complex
[9,10].
Because CD1b molecules are not polymorphic and Ac2SGL
is expressed only by Mtb and not by the nonvirulent mycobac-
terial strains, including the vaccine bacillus Calmette–Gue´rin,
the use of CD1b–Ac2SGL complex as a universal marker of Mtb
infection should be evaluated.
Our strategy was to exploit the phage display technology
to utilize its intrinsic advantages such as versatility, speed,
nonuse of animals, and the possibility to recognize poorly
immunogenic antigens among others [11]. A panel of anti-
body fragments specific for CD1b–Ac2SGL was obtained and
characterized. Such antibody fragments could be candidates
for the future development of diagnostic and therapeutic
tools for Mtb infection.Materials and methods
Isolation of human antibody-displaying phages recognizing
CD1b–Ac2SGL on CD1b-transfected THP-1 cellsPhage-displayed human antibody repertoire, bacteria, and
helper phage
The human single-fold scFv libraries I + J (Tomlinson I + J),
Escherichia coli TG1, and KM13 helper phage were all kindly
provided by the Medical Research Council (London, UK).
Ac2SGL loading on CD1b-transfected THP-1 cells
Human CD1b-transfected THP-1 cells [12] were seeded in four
wells of a 12-well culture plate at 106 cells/mL. A 10-lL volume
of Ac2SGL (20 lg/mL) was added into two wells with CD1b-
transfected THP-1 cells. Cells were mixed and cultured for
4 h at 37 C, 5% CO2 atmosphere in Roswell Park Memorial
Institute-1640 (RPMI-1640) medium without glutamine and
fetal bovine serum. The unloaded CD1b-transfected THP-1
cells were used for negative selection.
Phage selection on CD1b-transfected THP-1 cells loaded with
Ac2SGL
For negative selection, unloaded cells were harvested and
washed once with cold-sterile phosphate-buffered saline
(PBS) and two times with 2% skim milk (M) (Sigma, USA) in
cold-sterile PBS. All centrifugation steps were carried out at
4 C at 1000g for 5 min in an Eppendorf plate centrifuge. The
unloaded cells were incubated for 1 h at 4 C with 1013 naı¨ve
phage library particles in 2 mL cold-sterile 1% M–PBS. Cells
were spun down and the unbound phage-containing super-
natant was used for the positive selection. The loaded cells
were harvested as unloaded cells and were resuspended
and incubated for 1 h at 4 C with the preabsorbed unbound
phage-containing supernatant. The cells were then cen-
trifuged and unbound phages were eliminated by washing
the wells three times with PBS.
The cells were resuspended in 500 lL of trypsin solution
(Sigma, USA; 50 lg/mL) and incubated for 10 min at room
temperature (RT). Cells were spun down and the bound
phage-containing supernatant was carefully removed.
Selected phages were used to infect exponentially growing
E. coli TG1 cells. Infected cells were grown overnight in 2TY
agar plates containing 100 lg/mL ampicillin and 2% glucose.
Plates containing infected bacteria were scraped, and phage
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scale [13] and used as starting material for a new selection
round under the same conditions as described earlier. After
four selection rounds, two negative selection rounds were
conducted by adding Ac2SGL to mock THP-1 cells and
unloaded CD1b-transfected THP-1 cells, respectively. Individ-
ual phage-infected colonies were picked and used to produce
phagemid particles in a 96-well plate scale [12] to test their
antigen recognition properties.
Phage screening
Phage-containing supernatants from 96-well plates were
tested by enzyme-linked immunosorbent assay (ELISA) using
cells in suspension. THP1–CD1b cells (105), loaded/unloaded
with Ac2SGL in 100 lL of PBS-6%–bovine serum albumin
(BSA), were added to each ELISA plate well. Phage-
containing supernatants (50 lL) were added and incubated
(1 h at 4 C). After two washes (PBS-4%–fetal calf serum
[FCS]), horseradish peroxidase (HRP)/anti-M13 monoclonal
conjugate (GE Healthcare, UK; 100 lL/1:5,000 in PBS-4%–FCS)
was added and incubated (1 h at 4 C). The plates were
washed two times (PBS-4%–FCS) and 100 lL of 3,30,5,50-tetra
methylbenzidine (TMB) substrate solution (Sigma) was added.
The reaction was stopped by adding 100 lL of 1 M sulfuric
acid. The absorbance (Abs) was measured at 450 nm in a
microtiter plate reader (Bio-Tek Instruments). Clones with
Abs ratio (loaded/unloaded cells) > 3 were considered
positive.
Sequence analysis
Plasmid DNA from all positive clones was purified using
QIAprep Spin Miniprep Kit (QIAGEN, USA) and the inserts
were sequenced by Macrogen (Seoul, Korea) using specific pri-
mers complementary to the antibody fragment flanking
sequences. Immunogenetic analysis of variable regions was
performed using IMGT/V-QUEST (www.imgt.org/).
Recognition of CD1-Ac2SGL and lipids by phage clones
Positive phage clones were rescued on a 50-mL scale and
purified [13] for further evaluation.
Recognition of CD1-Ac2SGL by phage clones
Microtitration ELISA plates (Nunc MaxiSorp, USA) were coated
overnight at 4 C with the murine anti-CD1b monoclonal anti-
body (mAb) BCD1b3.1 (3 lg/mL) [14] in PBS. The plates were
blocked with 3% M–PBS for 1 h at RT. Recombinant human
CD1b loaded with Ac2SGL was then added at 5 lg/mL. Lipid
loading onto CD1b was performed as described by Garcia-
Alles et al. [15]. After 1 h of incubation at RT, three washes
with PBS were carried out and 108 phage particles in 50 lL
of 3% M–PBS were added and incubated again at RT for 1 h.
After three washes, 50 lL of anti-M13 mAb–HRP (1:5,000 in
3% M–PBS) was added and incubated for 1 h. After three more
washes, 50 lL of TMB substrate solution was added and incu-
bated for 10 min at RT. The reaction was stopped by adding
1 M sulfuric acid and the Abs was measured at 450 nm. The
ratio between the optical density (OD) reading against
CD1b–Ac2SGL and unloaded CD1b was determined and athreshold of positivity of 3 was established, which is above
the commonly used threshold ratio of 2 [16].
Binding of phage clones to the CD1b–Ac2SGL complex
The binding capacity of phage-selected clones was deter-
mined using microtitration ELISA plates (Nunc MaxiSorp,
USA) based on two methods: (a) using serial dilutions of
CD1b–Ac2SGL as coating (5 lg/mL to 80 ng/mL) with a con-
stant amount of phage (low-density coating ELISA) [17]; and
(b) using a fixed concentration of CD1b–Ac2SGL (coating) with
serial dilutions of purified phages; the lower phage concentra-
tion required to achieve 50% of maximum binding was taken
as reference for the indirect estimation of relative binding
capacity [18]. Both methods were performed as described in
the ‘‘Recognition of CD1-Ac2SGL by phage clones” section.
Recognition of lipids by phage clones
Each purified phage was tested by ELISA as follows: PolySorp
plates were coated with Ac2SGL and different lipids
(b-lactosylceramide, sphingomyelin, ganglioside GM1,
sulfatide, disulfate sulfatide, and a-galactosylceramide;
Avanti Polar Lipid, USA) in 10 lg/mL methanol and dried
overnight. The plates were blocked with 3% BSA/PBS buffer
for 1 h at RT. Then, 108 phage particles were added. After
2 h, the RT plates were washed three times with PBS.
Anti-M13 mAb conjugated to HRP was added and incubated
at RT for 1 h. After six washes, substrate solution addition
and Abs measurement were performed as described in the
‘‘Recognition of CD1-Ac2SGL by phage clones” section.
Production of soluble D11 (dAbj11) and evaluation
of recognition of CD1b–Ac2SGLProduction of soluble D11 (dAbj11)
Phagemid DNA from D11 phage clone was purified using QIA-
prep Spin Miniprep Kit (QIAGEN) and was transformed in
E. coli BL21 (DE3). A single colony was grown at 37 C in
50 mL of 2TY medium containing 2% glucose and 100 lg/
mL ampicillin until OD600 of cultures reached 0.6. Cells were
then harvested and grown for 6 h at 28 C in 50 mL of 2TY
with 100 lg/mL ampicillin and 1 mmol/L isopropyl-D-
thiogalactopyranoside. After centrifugation, periplasmic
extract was obtained using the osmotic shock method. In
brief, the cell pellet was resuspended in 1 mL of ice-cold
TES buffer (0.2 mol/L Tris–HCl, 0.5 mmol/L EDTA, 0.5 mol/L
sucrose, pH 8.0) and 15 mL of cold 0.2TES was subsequently
added. After incubation on ice for 30 min, the suspension was
centrifuged and periplasmic fraction containing the super-
natant was obtained and analyzed by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
Periplasmic fraction from a 100-mL culture, previously
equilibrated in binding buffer (BB; 50 mM NaH2PO4 and
300 mM NaCl), was used as the starting material for purifica-
tion by immobilized metal affinity chromatography with Ni-
Chelating Sepharose Fast Flow (GE, USA). The resin was
washed with BB containing 20 mmol/L imidazole. The anti-
body fragments were eluted with BB containing 250 mmol/L
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was desalted against PBS on a PD-10 column (GE, USA) and
analyzed by SDS-PAGE. Protein concentration of the final
sample was determined by BCATM Protein Assay Kit (Pierce,
USA) according to manufacturer’s instructions.
Recognition of CD1b–Ac2SGL by dAbj11
Serial dilutions (5 lg/mL to 130 ng/mL) of purified soluble
dAbj11 in PBS were added to a microtiter MaxiSorp ELISA
plate previously coated with the CD1b–Ac2SGL complex and
unloaded CD1b as described in the ‘‘Recognition of CD1-
Ac2SGL by phage clones” section. After 1-h incubation at RT,
the plate was washed with PBS-T and 9E10 mAb (directed to
the c-myc tag) (Sigma Aldrich, USA) at 10 lg/mL in PBS-3%–
BSA was added for 1 h at RT. After washing, an antimouse
immunoglobulin G–HRP (Sigma) diluted 1:3000 in PBS-3%–
BSAwas added for 1 h at RT. After washing, substrate solution
was added and Abs measurement was carried out as
described in the ‘‘Recognition of CD1-Ac2SGL by phage
clones” section.
Results
Isolation of phages recognizing CD1b–Ac2SGL on
CD1b-transfected THP-1 cells
Antibody-displaying phages were selected using Ac2SGL-
loaded CD1b-transfected THP-1 cells. Clones producing
phage-displayed antibody fragments able to recognize
CD1b–Ac2SGL on CD1b–THP-1 cells were identified by cell sus-
pension ELISA screening. To exclude nonspecific binding, the
phage clones were also tested against unloaded CD1b–THP-1Fig. 1 – Human antibody-displaying phages recognizing
CD1b–Ac2SGL on CD1b-transfected THP-1 cells.
Supernatants containing phage clones were tested by cell
suspension ELISA using Ac2SGL-loaded and Ac2SGL-
unloaded CD1b-transfected THP-1 cells. Bound phages were
detected by HRP–anti-M13 mAb. The ratio of the developed
color on loaded and unloaded CD1b-transfected THP-1 cells
was plotted for each phage clone. Optical density ratio > 3
was considered positive. pHEN1 phagemid clone-containing
supernatant was used as the negative control. Bars indicate
standard deviation. Ac2SGL = stearoyl-3-
hydroxyphthioceranoyl-20-sulfate-a-a0-D-trehalose;
ELISA = enzyme-linked immunosorbent assay;
HRP = horseradish peroxidase; mAb = monoclonal antibody.cells. While most of the analyzed phage clones bound non-
specifically to unloaded CD1b–THP-1 cells or showed a ratio
of loaded/unloaded cells > 3 (data not shown), eight clones
preferentially bound Ac2SGL-loaded CD1b–THP-1 cells
(Fig. 1). They were obtained after four rounds of panning
and two additional rounds of negative selection.
The eight phage clones recognizing CD1b–THP-1 cells were
sequenced. After sequence analysis, all clones except D11
corresponded to the expected scFV structure. D11 was deter-
mined to be a single, light-variable domain (kappa) antibody
(dAbj11).
Recognition of CD1b–Ac2SGL and different lipids by phage
clonesRecognition of CD1b–Ac2SGL by phage clones
The recognition of the selected phage clones was tested using
soluble CD1b–Ac2SGL complexes coated onto ELISA plates. All
the phage clones recognized the CD1b–lipid complex over
unloaded CD1b (Fig. 2). D11 (dAbj11) showed the highest reac-
tivity to loaded CD1b.
Binding of phage clones to CD1b–Ac2SGL
Binding and relative affinity of phage clones were evaluated
using either serial dilution of coated CD1b–Ac2SGL or serial
dilutions of phage clones with a specific concentration of
coated CD1b–Ac2SGL. All the phage clones demonstrated
binding to CD1b–Ac2SGL in the experimental conditions
assayed, and D11 (dAbj11), B8, and B9 showed the best bind-
ing capacities (Fig. 3A and B).
Recognition of different lipids by phage clones
The recognition of uncomplexed Ac2SGL and other glycosph-
ingolipids (b-lactosylceramide, sphingomyelin, gangliosideFig. 2 – Recognition of the CD1b–Ac2SGL complex by the
phage-displayed antibody fragments. ELISA plates were
coated with Ac2SGL-loaded and Ac2SGL-unloaded soluble
CD1b. Bound phages were detected with HRP–anti-M13
mAb. Absorbance ratios (loaded/unloaded cells) > 3 were
considered. Ac2SGL = Stearoyl-3-hydroxyphthioceranoyl-20-
sulfate-a-a0-D-trehalose; ELISA = enzyme-linked
immunosorbent assay; HRP = horseradish peroxidase;
mAb = monoclonal antibody.
Fig. 3 – Evaluation of CD1b–Ac2SGL binding of phage clones
and relative binding capacity. Relative binding capacity was
evaluated using (A) serial dilutions of the CD1b–Ac2SGL
complex (coating) and a fixed amount of phage particles
(108), or (B) different concentrations of phage clones and
constant concentration of the coating CD1b–Ac2SGL
complex. In both assays, bound phages were detected with
HRP–anti-M13 mAb. Ac2SGL = stearoyl-3-
hydroxyphthioceranoyl-20-sulfate-a-a0-D-trehalose;
CFU = colony forming units; ELISA = enzyme-linked
immunosorbent assay; HRP = horseradish peroxidase;
mAb =monoclonal antibody.
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by phage clones was studied by ELISA. All phage clones
showed specific recognition of Ac2SGL (Fig. 4).
Recognition of CD1b–Ac2SGL by soluble D11 (dAbj11)
The D11 (dAbj11) clone was selected to be further evaluated
in its soluble form taking into consideration the specific
recognition of CD1b–Ac2SGL, the binding relative affinity,
and its single-domain structure, which is advantageous for
future potential applications.
Single-domain antibody dAbj11, derived from the D11
clone, was expressed as a soluble antibody fragment in the
periplasmic extract of BL21 (DE3) cells and purified. The reac-
tivity of dAbj11 with CD1b–Ac2SGL versus unloaded CD1b
was confirmed using purified antibodies (Fig. 5).Discussion
The development of molecules specific for Mtb-infected cells
has important implications because these tools may facilitate
understanding of the mechanisms regulating host–pathogen
interactions in vivo. In addition, the development of new tools
capable of discriminating Mtb-infected cells may have poten-
tial applications in the diagnosis, treatment, and prevention
of TB. An ideal tool should detect markers that are only pro-
duced by Mtb and are independent of the genetic background
and polymorphisms of infected cells. Because of the lack of
CD1b polymorphism, Mtb lipid–CD1b complexes can be con-
sidered as universal Mtb infection markers [5]. In this regard,
sulfoglycolipids are specifically found in Mtb and among
them, Ac2SGL is antigenic and presented by CD1b [4].
A few mAbs against Mtb lipids obtained by hybridoma
technology are now available [19–21]. The production of a
ligand obtained from a human Fab antibody library recogniz-
ing the human CD1d–a-galactosylceramide (a-GalCer) com-
plex [22] has been reported. These Fab fragments specifically
detected the soluble complexes as well as those on antigen-
presenting cells in culture and in vivo in dendritic cells from
transgenic mice [22].
In this study, we used a human synthetic naive library to
isolate antibody fragments against CD1b–Ac2SGL complexes.
Phage-displayed antibody fragments were selected using
CD1b-transfected THP-1 cells loadedwith the Mtb sulfoglycol-
ipid Ac2SGL. We decided to use this system to display the gly-
colipid antigen on the surface of human antigen-presenting
cells trying to reproduce, as much as possible, the conditions
in which the CD1b–Ac2SGL complex is presented in vivo. A
panel of eight phage-displayed antibodies was obtained using
our approach. All of them were able to specifically recognize
the CD1b–Ac2SGL complex over unloaded CD1b. At the same
time, all the selected phage clones recognize Ac2SGL not com-
plexed to CD1b, with no recognition of other lipid molecules,
which adds extra potential versatility to these ligands. Previ-
ously, we obtained similar results with a filamentous phage
displaying a T-cell receptor (TCR) fragment specific for this
complex [23]. Regarding the recognition of plastic-bound Ac2-
SGL, it should be noted that such recognition was less intense
than the recognition of the CD1b complexes. This finding
could be related to the recognition of lipid regions also avail-
able for interaction with the antibody when the lipid is
included in the complex.
One interesting result was the unexpected selection of a
single-variable light-domain antibody using a synthetic scFv
library. It represents a ‘‘defective” clone that only received
the light-variable chain during the construction of the library.
Single-domain antibodies represent an interesting alterna-
tive for diagnosis and therapy due to their potential advan-
tages such as stability, tissue penetration, low
immunogenicity, and recognition of cryptic epitopes among
others [24–27]. In the case of single-domain variable light-
chain antibodies, although less studied, several reports high-
light their potential advantages and usefulness in diagnosis
and therapy [28–32].
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Fig. 4 – Recognition of different lipids by phage clones (A8, B8, B9, D11, E4, G1, G3, and G9) using lipid-coated plates. Bound
phages were detected with HRP–anti-M13 mAb. 1 = b-lactosylceramide, 2 = sphingomyelin, 3 = ganglioside GM1; 4 = sulfatide;
5 = disulfate sulfatide; 6 = a-galactosylceramide; 7 = Ac2SGL; 8 = phosphate-buffered saline. Bars indicate standard deviation.
Ac2SGL = stearoyl-3-hydroxyphthioceranoyl-20-sulfate-a-a0-D-trehalose; ELISA = enzyme-linked immunosorbent assay;
HRP = horseradish peroxidase; mAb = monoclonal antibody.
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Fig. 5 – Soluble, single-domain antibody dAbj11 recognizes
the CD1b–Ac2SGL complexes. Immunoreactivity of purified
dAbj11 against recombinant CD1b–Ac2SGL complexes.
Bound antibody fragments were detected by ELISA using
HRP-labeled 9E10 mAb. Results are presented as OD450 nm
± standard deviation. Ac2SGL = stearoyl-3-
hydroxyphthioceranoyl-20-sulfate-a-a0-D-trehalose;
ELISA = enzyme-linked immunosorbent assay;
HRP = horseradish peroxidase; mAb = monoclonal antibody;
OD = optical density.
126 I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 5 ( 2 0 1 6 ) 1 2 0 –1 2 7Considering the potential importance of the immune
response to mycobacterial lipid antigens presented by CD1b
molecules [5,7,33,34], and the identification of specific
CD1b–Mtb lipid complexes associated with Mtb infection [4],
the use of TCR-like structures recognizing these
complexes for the development of diagnostic and therapeutic
tools for TB is an option that deserves to be explored in the
future.
The high relative binding capacity and specificity of the
D11 (dAbj11) phage clone for the CD1b–Ac2SGL complex
and its recognition of free Ac2SGL support using this clone
for further development of diagnostic and therapeutic
applications.
In conclusion, we have identified human antibody frag-
ments capable of recognizing the CD1b–Ac2SGL complex.
These antibodies might be evaluated as potential diagnostic,
therapeutic, and research tools. The simple phage-selection
method we have developed can be expanded to obtain larger
panels of human antibody fragments in the search for func-
tional antibodies against different CD1b–mycobacterial lipid
complexes.Conflicts of interest
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